StockNews.com Begins Coverage on Oragenics (NYSE:OGEN)

StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a report issued on Saturday morning. The brokerage issued a sell rating on the stock.

Oragenics Trading Down 1.0 %

Shares of NYSE:OGEN opened at $0.51 on Friday. The company has a market capitalization of $2.29 million, a price-to-earnings ratio of -0.06 and a beta of 0.50. Oragenics has a 12-month low of $0.47 and a 12-month high of $7.74. The business has a 50-day moving average price of $1.09 and a 200 day moving average price of $1.41.

Oragenics (NYSE:OGEN) last announced its earnings results on Friday, August 9th. The company reported ($0.51) earnings per share for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC purchased a new position in shares of Oragenics, Inc. (NYSE:OGEN) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned approximately 0.51% of Oragenics as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 18.71% of the company’s stock.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.